Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
0.454% stannous fluoride
Colgate Oral Care
Calculus, Dental
1 trial -
0.454% stannous fluoride
Colgate Oral Care
Oral Malodor
1 trial -
0.9 % w/v Sodium Chloride Injection, Reblozyl 25 mg powder for solution for injection, Reblozyl 75 mg powder for solution for injection
Celgene Europe Limited
Anemia associated with myeloproliferative neoplasm (MPN)-associated myelofibrosis (MF)
1 trial -
1% Clascoterone Cream
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Acne Vulgaris
1 trial -
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Basket Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients with Anti-N-Methyl-D-Aspartic Acid Receptor (NMDAR) or Anti-Leucine-Rich Glioma-Inactivated 1 (LGI1) Encephalitis
Hoffmann-La Roche
NMDAR or LGI1 mediated autoimmune Encephalitis
1 trial -
ATLG
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Hematopoietic Stem Cell Transplantation
1 trial -
AXS-14 (Esreboxetine)
Axsome Therapeutics
Fibromyalgia
1 trial -
Adapalene 0.3% / BPO 2.5% gel
Galderma Australia Pty Ltd
Acne Vulgaris
1 trial -
BENDAMUSTINE HYDROCHLORIDE, PREDNISOLONE , CYCLOPHOSPHAMIDE, LENALIDOMIDE, PREDNISONE, DOXORUBICIN HYDROCHLORIDE, Golcadomide, Golcadomide, PEGFILGRASTIM, Golcadomide, BENDAMUSTINE HYDROCHLORIDE, RITUXIMAB, LENALIDOMIDE, RITUXIMAB, VINCRISTINE SULFATE, LENALIDOMIDE, LENALIDOMIDE, CYCLOPHOSPHAMIDE, Golcadomide, DOXORUBICIN HYDROCHLORIDE
Celgene Europe Limited
Relapsed/Refractory Follicular Lymphoma
1 trial -
BIOTIN, Medebiotin Fuerte solución inyectable, Medebiotín Fuerte Comprimidos
The George Institute
Metilcrotonilglicinuria, biotinidasa deficit
1 trial -
BaidI Quzhi granule
Universal Integrated
Acne Vulgaris
1 trial -
Botulinum Toxin type A (intradermal / submucosal injection at pain area)
The First People's Hospital of Lianyungang
Trigeminal Neuralgia
1 trial -
CARBOPLATIN, CISPLATIN, PEGFILGRASTIM, PEMETREXED, BL-B01D1
Bristol-Myers Squibb Australia Pty Ltd
EGFR-mutated Non-small Cell Lung Cancer
1 trial -
CISPLATIN, BL-B01D1, GEMCITABINE, PEGFILGRASTIM, CARBOPLATIN
Bristol-Myers Squibb Australia Pty Ltd
Metastatic urothelial cancer
1 trial -
CYCLOPHOSPHAMIDE, FLUDARABINE PHOSPHATE, DEXAMETHASONE, DEXAMETHASONE, POMALIDOMIDE, FLUDARABINE PHOSPHATE, DEXAMETHASONE, DEXAMETHASONE, DEXAMETHASONE SODIUM PHOSPHATE, CYCLOPHOSPHAMIDE, POMALIDOMIDE, DEXAMETHASONE, CARFILZOMIB, POMALIDOMIDE, DARATUMUMAB, GPRC5D-TARGETED CAR T, DEXAMETHASONE SODIUM PHOSPHATE, POMALIDOMIDE, TOCILIZUMAB
Celgene Europe Limited
Relapsed or Refractory and Lenalidomide exposed Multiple Myeloma
1 trial -
Cantharidin
Verrica Pharmaceuticals
Common Warts (Verruca Vulgaris)
1 trial -
Casgevy 4 - 13 x 10^6 cells/mL dispersion for infusion, BUSULFAN, FILGRASTIM, PLERIXAFOR
Vertex Pharmaceuticals (Australia) Pty.
Transfusion-dependent β-thalassemia (TDT)
1 trial -
Casgevy 4 - 13 x 10^6 cells/mL dispersion for infusion, BUSULFAN, FILGRASTIM, PLERIXAFOR
Vertex Pharmaceuticals (Australia) Pty.
Transfusion-Dependent-Thalassemia
1 trial -
Celestone Cronodose suspensión inyectable, Ropivacaína Altan 7,5 mg/ml solución inyectable EFG, PLATELET CONCENTRATE
The George Institute
CHRONIC OMALGIA
1 trial -
Cendakimab
Celgene Europe Limited
Eosinophilic esophagitis
1 trial -
Clascoterone
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Acne Vulgaris
1 trial -
Compound Realgar-Indigo Naturalis Formula Plus Retinoic Acid
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Acute Promyelocytic Leukaemia
1 trial -
DANAZOL , BUSULFAN , -, POMALIDOMIDE , FEDRATINIB, RUXOLITINIB, PEGFILGRASTIM , HYDROXYCARBAMIDE , PEGINTERFERON ALFA-2A , -
Celgene Europe Limited
Primary myelofibrosis, post-polycythemia vera myelofibrosis , or post-essential thrombocythemia myelofibrosis
1 trial -
DMT310
Dermata Therapeutics
Acne Vulgaris
3 trials
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources